CLAIMS

1. A delta-like ligand 4 (Dll4) antagonist for use in preventing, treating or ameliorating multiple sclerosis, wherein the Dll4 antagonist is an antibody or fragment thereof that specifically binds human Dll4 (hDll4) and blocks Dll4-Notch signal pathways, and the antagonist blocks an interaction between Dll4 and Notch receptor, thereby increasing the number of Treg cells and the multiple sclerosis is prevented, treated or ameliorated, and wherein the antibody or fragment thereof comprises a heavy chain variable region (HCVR) comprising heavy chain CDR1, CDR2 and CDR3 sequences of SEQ ID NOs: 22, 24 and 26, respectively, and a light chain variable region (LCVR) comprising light chain CDR1, CDR2 and CDR3 sequences of SEQ ID NOs: 30, 32 and 34, respectively.

2. The Dll4 antagonist for use according to claim 1, wherein:

(i) the antibody or fragment thereof comprises a HCVR sequence of SEQ ID NO:20 or SEQ ID NO:116; and

(ii) the antibody or fragment thereof comprises a LCVR sequence of SEQ ID NO:28 or SEQ ID NO:118.

3. The Dll4 antagonist for use according to claims 1 or 2, wherein the antibody or fragment thereof comprises a HCVR/LCVR combination of SEQ ID NO:20/28 or 116/118.

4. The Dll4 antagonist for use according to any one of the preceding claims in combination with at least one additional therapeutic agent selected from immunosuppressant, anti-inflammatory agent, and analgesic agent, optionally wherein:

(i) the additional therapeutic agent is at least one selected from glucocorticoids, cyclosporin, methotrexate, non-steroidal anti-inflammatory drugs (NSAIDs), TNF-α antagonists, IL-1 antagonists, IL-6 antagonists, and opioids; or

(ii) the Dll4 antagonist and at least one additional therapeutic agent are for concurrent or sequential administration.

5. Use of a delta-like ligand 4 (Dll4) antagonist in the manufacture of a medicament for preventing, treating or ameliorating multiple sclerosis, wherein the Dll4

antagonist is an antibody or fragment thereof that specifically binds human Dll4 (hDll4) and blocks Dll4-Notch signal pathways, and the antagonist blocks an interaction between Dll4 and Notch receptor, thereby increasing the number of Treg cells and the multiple sclerosis is prevented, treated or ameliorated, and wherein the antibody or fragment thereof comprises a heavy chain variable region (HCVR) comprising heavy chain CDR1, CDR2 and CDR3 sequences of SEQ ID NOs: 22, 24 and 26, respectively, and a light chain variable region (LCVR) comprising light chain CDR1, CDR2 and CDR3 sequences of SEQ ID NOs: 30, 32 and 34, respectively.

6. The use according to claim 5, wherein:

(i) the antibody or fragment thereof comprises a HCVR sequence of SEQ ID NO:20 or SEQ ID NO:116; and

(ii) the antibody or fragment thereof comprises a LCVR sequence of SEQ ID NO:28 or SEQ ID NO:118.

7. The use according to claim 5 or 6, wherein the antibody or fragment thereof comprises a HCVR/LCVR combination of SEQ ID NO:20/28 or 116/118.